Home › Compare › CYTO vs EQR

CYTO vs EQR: Dividend Comparison 2026

CYTO yields 666.67% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYTO wins by $608115.61M in total portfolio value
10 years
CYTO
CYTO
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full CYTO calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — CYTO vs EQR

📍 CYTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYTO + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CYTO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTO
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, CYTO beats the other by $399,126,861,339.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTO + EQR for your $10,000?

CYTO: 50%EQR: 50%
100% EQR50/50100% CYTO
Portfolio after 10yr
$304057.85M
Annual income
$234,780,512,145.92/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CYTO
No analyst data
Altman Z
-1.2
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTO buys
0
EQR buys
0
No recent congressional trades found for CYTO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTOEQR
Forward yield666.67% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$608115.66M ✓$47.8K
Annual income after 10y$469,561,018,816.25 ✓$5,475.61
Total dividends collected$596792.85M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CYTO vs EQR ($10,000, DRIP)

YearCYTO PortfolioCYTO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$77,367$66,666.67$11,380$679.82+$66.0K → CYTO
2$564,818$482,035.31$13,014$837.25+$551.8K → CYTO
3$3,893,246$3,288,890.67$14,961$1,036.20+$3.88M → CYTO
4$25,352,760$21,186,987.16$17,297$1,289.22+$25.34M → CYTO
5$156,070,781$128,943,327.59$20,121$1,613.15+$156.05M → CYTO
6$908,837,800$741,842,064.29$23,561$2,030.84+$908.81M → CYTO
7$5,009,769,782$4,037,313,336.56$27,783$2,573.54+$5009.74M → CYTO
8$26,159,339,258$20,798,885,591.56$33,013$3,284.39+$26159.31M → CYTO
9$129,490,317,125$101,499,824,118.87$39,547$4,223.51+$129490.28M → CYTO
10$608,115,658,140$469,561,018,816.25$47,791$5,475.61+$608115.61M → CYTO

CYTO vs EQR: Complete Analysis 2026

CYTO — Stock

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Full CYTO Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CYTO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTO vs SCHDCYTO vs JEPICYTO vs OCYTO vs KOCYTO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.